Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Listeria Susceptibility in Patients With Multiple Myeloma Receiving Daratumumab-Based Therapy

Listeria Susceptibility in Patients With Multiple Myeloma Receiving Daratumumab-Based Therapy This case-control study examines the association of Listeria monocytogenes susceptibility with the receipt of daratumamab-based therapy in Canadian patients with multiple myeloma. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

Listeria Susceptibility in Patients With Multiple Myeloma Receiving Daratumumab-Based Therapy

Loading next page...
 
/lp/american-medical-association/listeria-susceptibility-in-patients-with-multiple-myeloma-receiving-c4SnOLMLoV
Publisher
American Medical Association
Copyright
Copyright 2019 American Medical Association. All Rights Reserved.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2019.5098
Publisher site
See Article on Publisher Site

Abstract

This case-control study examines the association of Listeria monocytogenes susceptibility with the receipt of daratumamab-based therapy in Canadian patients with multiple myeloma.

Journal

JAMA OncologyAmerican Medical Association

Published: Feb 27, 2020

References